TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study | Synapse
March 3, 2026
TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study
Key Points
Tyrosine kinase inhibitors combined with TACE may improve outcomes for patients with HCC.
Overall survival rates showed significant variation, emphasizing the need for personalized treatments.
The analysis utilized real-world data from multiple centers to assess efficacy and safety.
Findings indicate potential benefits of PD-1 inhibitors, warranting further investigation into their role.